Ponatinib and Cytarabine

PreclinicalSmall molecule

VVersailles Hospital

Ponatinib and Cytarabine is one of 42 small molecule programs targeting Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

MyeloidCompleted

LeukemiaPhase 1/Phase 2

Active, not recruiting

MyeloidPreclinical

Completed

Competition

Competitive Landscape

508 competitors in Leukemia

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Phase 3

31 2

Fludara

Sanofi

Phase 3

22 3

Rituxan

Roche

Phase 3

16 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

58 5

Fludara

Sanofi

Phase 3

11 6

Vepesid

AAvyxa

Phase 3

25 7

Oncovin

Eli Lilly

Phase 3

9 8

Decadron

AAspen Global Incorporated

Phase 3

24 9

Oncovin

EEastern Cooperative Oncology Group

Phase 3

15 10

Clolar

GGenzyme, a Sanofi Company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myeloid1 trial

A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission

Completed·VVersailles Hospital·Preclinical·NCT02428543·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ponatinib and Cytarabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ponatinib and Cytarabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ponatinib and Cytarabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Versailles Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVersailles Hospital

Ponatinib and Cytarabine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myeloid1 trial

References

Drug Info

Quick Facts

Related News